Cell and gene therapies represent a paradigm shift in the development of pharmaceutical products. These treatments not only often promise to cure disease but also represent an evolution in product manufacturing and delivery. Understanding the barriers and risks early in drug development is paramount for ensuring these therapies deliver on their promises for patients.

Drawing on experience working with biopharmaceutical innovators on the commercialization and launch of cell and gene therapies, leaders from across Fishawack Health have developed a series of articles on the evolving landscape. Experts from Avalere, which joined Fishawack Health in June 2022, are featured in a discussion of key regulatory challenges and the impact of US policy changes at each stage of the cell and gene product life cycle. They focus on the impact on product developers, highlighting considerations that will equip companies to plan effectively.

The report covers the challenges and opportunities manufacturers face when commercializing cell and gene products. Along with recommendations from our experts, the articles also include insights from stakeholders such as biopharmaceutical industry leaders, researchers, and patients.

Download the report to find:

• An interview with Professor Francesco Dazzi, Medical Lead Cell Therapy, BioPharmaceuticals R&D at AstraZeneca, on the company’s novel cell therapy pipeline for chronic diseases
• Patient and market access insights on leveraging CRISPR technology for hematologic diseases
• Trends shaping the future of personalized medicine
• Steps for communicating the complex science to a variety of stakeholders

For more information about the cell and gene therapies market, connect with us.